Featured Research

from universities, journals, and other organizations

Potential drug compound attacks Parkinson's on two fronts

Date:
June 20, 2013
Source:
Scripps Research Institute
Summary:
Scientists have found a compound that could counter Parkinson’s disease in two ways at once. Scientists now describe a “dual inhibitor” that attacks a pair of proteins closely associated with development of Parkinson’s disease.

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found a compound that could counter Parkinson's disease in two ways at once.

Related Articles


In a new study published recently online ahead of print by the journal ACS Chemical Biology, the scientists describe a "dual inhibitor" -- two compounds in a single molecule -- that attacks a pair of proteins closely associated with development of Parkinson's disease.

"In general, these two enzymes amplify the effect of each other," said team leader Phil LoGrasso, a TSRI professor who has been a pioneer in the development of JNK inhibitors for the treatment of neurodegenerative diseases. "What we were looking for is a high-affinity, high-selectivity treatment that is additive or synergistic in its effect -- a one-two punch."

That could be what they found.

This new dual inhibitor attacks two enzymes -- the leucine-rich repeat kinase 2 (LRRK2) and the c-jun-N-terminal kinase (JNK) -- pronounced "junk." Genetic testing of several thousand Parkinson's patients has shown that mutations in the LRRK2 gene increase the risk of Parkinson's disease, while JNK has been shown to play an important role in neuron (nerve cell) survival in a range of neurodegenerative diseases. As such, they have become highly viable targets for drugs to treat disorders such as Parkinson's disease.

A dual inhibitor ultimately would be preferred over separate individual JNK and LRRK2 inhibitors because a combination molecule would eliminate complications of drug-drug interactions and the need to optimize individual inhibitor doses for efficacy, the study noted.

Now the team's new dual inhibitor will need to be optimized for potency, high selectivity (which reduces off-target side effects) and bioavailability so it can be tested in animal models of Parkinson's disease.


Story Source:

The above story is based on materials provided by Scripps Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yangbo Feng, Jeremy W. Chambers, Sarah Iqbal, Marcel Koenig, HaJeung Park, Lisa Cherry, Pamela Hernandez, Mariana Figuera-Losada, Philip V. LoGrasso. A Small Molecule Bidentate-Binding Dual Inhibitor Probe of the LRRK2 and JNK Kinases. ACS Chemical Biology, 2013; 130610145315006 DOI: 10.1021/cb3006165

Cite This Page:

Scripps Research Institute. "Potential drug compound attacks Parkinson's on two fronts." ScienceDaily. ScienceDaily, 20 June 2013. <www.sciencedaily.com/releases/2013/06/130620111138.htm>.
Scripps Research Institute. (2013, June 20). Potential drug compound attacks Parkinson's on two fronts. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2013/06/130620111138.htm
Scripps Research Institute. "Potential drug compound attacks Parkinson's on two fronts." ScienceDaily. www.sciencedaily.com/releases/2013/06/130620111138.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins